On February 21, 2025, the United States Supreme Court delivered a unanimous decision in Wisconsin Bell, Inc. v. United States ex rel. Heath , significantly broadening the scope of the False Claims Act (FCA) .
On March 21, 2025, the Financial Crimes Enforcement Network (FinCEN) announced significant changes to the Beneficial Ownership Information Reporting (BOIR) requirements.
On March 11, 2025, the Financial Crimes Enforcement Network (FinCEN) issued a Southwest Border Geographic Targeting Order (GTO) aimed at Money Service Businesses (MSBs).
On March 2, 2025, the Treasury has confirmed that FinCEN will no longer enforce any penalties or fines associated with the BOI filing requirement.
FinCEN has extended the now (again) mandatory BOIR filing deadline by 30 calendar days to March 21, 2025. The only exception to the mandatory filing requirement are the Plaintiffs in the National Small Business United v. Yellen, No. 5:22-cv-01448 (N.D. Ala) action.
In California, the definition of “domestic violence” extends far beyond the traditional notions of physical and emotional harm. The definition of what constitutes “abuse” and “domestic violence” is no longer limited to acts inflicting physical injury.
The FDA has recently issued draft guidance (non-binding recommendations) for drug and biological product sponsors and computer programmers regarding the use of Machine Learning (ML) and artificial intelligence (AI) to support regulatory decision-making about the safety, effectiveness, or quality of drugs.
In California, the definition of “domestic violence” extends far beyond the traditional notions of physical and emotional harm. The definition of what constitutes “abuse” and “domestic violence” is no longer limited to acts inflicting physical injury.
Considering conflicting rulings, businesses remain understandably confused about whether to file their mandated Beneficial Ownership Reports with FinCen. As of this writing, the answer remains that businesses may file but are not (yet) required to do so.
On December 5, 2024, the FDA’s Center for Drug Evaluation and Research (CDER), along with the Center for Biologics Evaluation and Research (CBER) and the Oncology Center of Excellence (OCE) issued draft guidance concerning expedited programs for serious conditions.